CLCN2 Knockout HEK293 Cell Line
Cat.No.:
EDC09609
Species:
Human
Cell Name:
HEK293
Gene:
CLCN2
Gene ID:
1181
Size:
1×10⁶cells
CLCN2 Knockout Cell Line (HEK293) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC09609 |
|---|---|
| Product Name | CLCN2 Knockout Cell Line (HEK293) |
| Cell Line | HEK293 |
| Cellosaurus ID | CVCL_0045 |
| Cell Line Synonyms | Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293 |
| Gene |
CLCN2 |
| NCBI Gene ID | |
| Gene Synonyms | CIC-2|CLC2|ECA2|ECA3|EGI11|EGI3|EGMA|EJM6|EJM8|FHA2|FHII|HALD2|LKPAT|clC-2 |
| Summary |
This gene encodes a voltage-gated chloride channel. The encoded protein is a transmembrane protein that maintains chloride ion homeostasis in various cells. Defects in this gene may be a cause of certain epilepsies. Four transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2012]
|
| Associated Diseases | Non-tumor |
| Morphology | Adherent |
| Passage Ratio | 1/5,2days |
| Complete Culture Medium | DMEM + 10% FBS |
| Freezing Medium | 95% Complete culture medium+ 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: HEK293 | STR Info (Cell bank) Cell Line: HEK293 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | X | ||
| CSF1P0 | 12 | 11 | 12 | |
| D2S1338 | 19 | 19 | ||
| D3S1358 | 15 | 17 | 15 | 17 |
| D5S818 | 8 | 8 | 9 | |
| D7S820 | 11 | 12 | 11 | 12 |
| D8S1179 | 12 | 14 | 12 | 14 |
| D13S317 | 12 | 14 | 12 | 14 |
| D16S539 | 9 | 13 | 9 | 13 |
| D18S51 | 17 | 18 | 17 | 18 |
| D19S433 | 15 | 18 | 15 | 18 |
| D21S11 | 28 | 30.2 | 28 | 30.2 |
| FGA | 23 | 23 | ||
| Penta D | 9 | 10 | 9 | 10 |
| Penta E | 7 | 15 | 7 | 15 |
| TH01 | 7 | 9.3 | 7 | 9.3 |
| TPOX | 11 | 11 | ||
| vWA | 16 | 19 | 16 | 19 |
| D6S1043 | 11 | 11 | ||
| D12S391 | 19 | 21 | 11 | 15 |
| D2S441 | 11 | 15 | 11 | 15 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying CLCN2 function, CLCN2 Knockout HEK293 Cell Line or CLCN2 overexpression HEK293 Cell Line?
The choice depends on whether you are studying CLCN2 (chloride channel 2, CLC-2)'s role as a plasma membrane voltage-gated Cl⁻ channel or modeling leukoencephalopathy and CLCN2-mediated aldosteronism. The Knockout line is the standard tool for asking whether CLCN2 is required for these processes — CLCN2 is a CLC family member that, unlike CLC-7, functions as a true plasma membrane voltage-gated Cl⁻ channel activated by hyperpolarization, cell swelling, and acidic pH; CLCN2 has roles in maintaining cellular Cl⁻ homeostasis, brain extracellular ion balance, and aldosterone production. Overexpression is useful for studying CLCN2 gain-of-function effects.
For neurological and endocrine research, the EDITGENE CLCN2 Knockout in HEK293 enables structure-function studies — CLCN2 biallelic loss-of-function mutations cause leukoencephalopathy with ataxia (LKPAT, brain white matter disease) and infertility; gain-of-function mutations cause familial hyperaldosteronism type II. Rescue with wild-type, channel-dead, or disease-mutant CLCN2 enables comprehensive disease modeling. The knockout is valuable for studying voltage-gated Cl⁻ channel biology, leukoencephalopathy mechanisms, and aldosterone production regulation.
What are the application scenarios for this model?
Primary applications:
• Voltage-gated Cl⁻ current: whole-cell patch clamp analysis of hyperpolarization-activated Cl⁻ currents in CLCN2-null cells.
• LKPAT leukoencephalopathy modeling: rescue with biallelic loss-of-function patient mutations for genotype-function studies.
• Familial hyperaldosteronism modeling: rescue with gain-of-function CLCN2 mutations (e.g., G24D, R172Q, Y26N) for type II hyperaldosteronism studies.
• Aldosterone production: in heterologous adrenocortical-relevant contexts, CLCN2-induced membrane depolarization and aldosterone synthesis.
EDITGENE recommends this model for researchers investigating voltage-gated Cl⁻ channel biology and CLCN2-related neurological/endocrine disease.
Is this CLCN2 Knockout HEK293 Cell Line compatible with overexpression rescue experiments?
Yes. CLCN2 rescue experiments require attention to plasma membrane voltage-gated channel architecture:
• Construct design: use a codon-modified CLCN2 sequence with a small intracellular tag (FLAG, HA). CLCN2 has the canonical CLC architecture — preserve membrane topology.
• Surface localization validation: confirm plasma membrane localization before electrophysiology assays.
• Channel-dead rescue: gating residue mutations abolish hyperpolarization-activated Cl⁻ currents.
• Familial hyperaldosteronism mutation rescue: gain-of-function mutations (G24D, R172Q, Y26N) enable disease modeling.
• Functional readout: rescue should restore hyperpolarization-activated Cl⁻ currents by patch clamp.
HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for systematic CLCN2 mutation analysis.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
download